جستجوی مقالات مرتبط با کلیدواژه "bioprosthetic heart valve" در نشریات گروه "پزشکی"

Rheumatic heart disease and consequent disease of heart valves continues to place a heavy burden on health services providers, especially in developing countries. The ideal heart valve substitute has yet to be found, and new valve designs with innovative processing technologies are being introduced. In this regard, the new Sorin Freedom Solo bovine pericardial valve is designed for supra-annular implantation, is stent-less and without a fabric sewing cuff, and is implanted with a single suture line technique. In this report, we present our initial experience with these substitutes.
Between October 2006 and March 2007, nine patients underwent surgery for aortic valve replacement with this biological prosthesis. Seven patients had aortic insufficiency (AI); one, stenosis (AS); three combined, AS/AI; the mean patient age was 53.11±17.54. Standard median sternotomy incision and cardiopulmonary bypass with mild hypothermia was used for all patients. Postoperative results, morbidity and mortality were assessed and hemodynamic data were obtained by echocardiography (mean and peak gradients, valve function) at follow-up.
All patients survived the procedure and were discharged from hospital. Mean duration of cardiopulmonary bypass was 92.44±24.65 minutes and mean cross-clamp time was 72.44±16.75 minutes. Mean time of intensive care unit stay was 3.44±1.66 days. Mean and peak transvalvular gradients were 6.5±2.88 mmHg and 17.50±5.68mmHg, respectively at followup (about 8 months). Four patients had trivial AI and there were no paravalvular leakages. All patients are alive and well at the time of this writing and no patient is taking anticoagulants.
Our initial experience with the new generation pericardial stentless aortic valve, Freedom Solo, appears to be a promising aortic valve substitute for patients requiring aortic valve replacement. Long-term durability and performance remain to be determined

To avoid the fetal and maternal risks associated with anticoagulant therapy during pregnancy, the use of bioprostheses has been advocated for young women with cardiac valve disease who may later wish to bear children. The aim of this historical cohort study was to evaluate pregnancy outcome in women with bioprosthetic heart valves.
Fifteen women who became pregnant after bioprosthetic heart valve replacement were followed during 28 pregnancies. Eleven had undergone isolated mitral, 3 had aortic and 1 had tricuspid valve replacement. Their ages at the time of surgery ranged from 14 to 1 years (mean 19.85±5.54).
All the women were in sinus rhythm at the time of gestation. No embolic episodes ccurred either after surgery or during pregnancy, labor or the puerperium.
B>Results- Fetal loss occurred in 7 of the 28 pregnancies (25%), and was due to abortion (N=5), re-maturity and neonatal death (N=2). No congenital malformation was seen. The mean irth weight in 21 pregnancies was 3082c, and only 1 newborn had low birth weight 2100gr). Two cases of rapid degeneration of bioprosthetic valves leading to reoperation ccurred in two patients, one in the 7th month of pregnancy and the other 4 months after elivery.
Bioprosthetic valves can be considered the most suitable prosthetic heart valve mployed in women of childbearing age because anticoagulants can be avoided, so the isk of embryopathy following the use of anticoagulant drugs is omitted.